MTEMQ (Molecular Templates) Other Stockholders Equity: $-0.00 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MTEMQ Molecular Templates Inc MTEMQ
12 GF Score
Price $0.00
View Full Analysis

What is Molecular Templates Other Stockholders Equity?

Molecular Templates MTEMQ 12 Other Stockholders Equity is $-0.00 Mil as of Jun. 2024. GuruFocus rates MTEMQ with a GF Score™ of 12/100.

Molecular Templates's Other Stockholders Equity for the quarter that ended in Jun. 2024 was $-0.00 Mil.

Molecular Templates's quarterly Other Stockholders Equity declined from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($-0.00 Mil) and declined from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($-0.00 Mil).

Molecular Templates's annual Other Stockholders Equity declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).

Molecular Templates Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Molecular Templates's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Templates Other Stockholders Equity Chart

Molecular Templates Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 0.00

Molecular Templates Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 -0.00
MTEMQ
12GF Score
Molecular Templates Inc MTEMQ
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Templates Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Molecular Templates (MTEMQ) has a Other Stockholders Equity of $-0.00 Mil as of Jun. 2024. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Molecular Templates and its competitors.
Is Molecular Templates' Other Stockholders Equity too high?
Molecular Templates' current Other Stockholders Equity is $-0.00 Mil. Overall, Molecular Templates has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Molecular Templates' Other Stockholders Equity compare to GRTSQ and ARTHQ?
Molecular Templates' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Molecular Templates and its competitors. Molecular Templates's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Templates stock overvalued right now?
Molecular Templates (MTEMQ) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Molecular Templates' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Molecular Templates (MTEMQ), the current Other Stockholders Equity is $-0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecular Templates Business Description

Address 9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
12GF Score

Get the complete analysis for MTEMQ

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price